As pointed out by Lai and colleagues, a large ongoing trial (NCT03512197) aimed at assessing the off-target kinase effects of midostaurin in patients without FLT3 mutation was designed without an age limit and is expected to provide insights on the tolerability of midostaurin in older AML patients [45]. The gene discussed is FLT3; the disease is acute myeloid leukemia.